Adlai Nortye (ANL) Change in Receivables (2024 - 2025)
Adlai Nortye (ANL) reported Change in Receivables of $231000.0 for Q2 2025, down 24.01% on a QoQ basis from $304000.0 in Q4 2024.
Adlai Nortye (ANL) has 2 years of Change in Receivables data on file, last reported at $231000.0 in Q2 2025.
- Quarterly Change in Receivables changed N/A year-over-year to $231000.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $231000.0 (changed N/A YoY) and the FY2024 annual result came in at $304000.0, changed N/A from the prior year.
- Change in Receivables declined to $231000.0 in Q2 2025 per ANL's latest filing, from $304000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $304000.0 in Q4 2024 and bottomed at $231000.0 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 208,524.00 |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | -39.80 Mn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | -1.20 Mn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 110.42 Mn |
| 10 | Adlai Nortye | 23,840.00 | -8.03 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 231,000.00 |
| Jun 30, 2025 | 231,000.00 |
| Dec 31, 2024 | 304,000.00 |
| Dec 31, 2024 | 304,000.00 |